tirzepatide nerve pain Diabetes Medication May Reduce Risk for Peripheral Neuropathy Diabetes drugs linked to higher
Description
Covers 2, 5, and 10 mg vials.
Methods This is a cohort study combining several population-wide databases and covering a Spanish population of five million inhabitants, including all adults with obesity who initiated treatment with either GLP-1RA or SGLT-2i for type 2 diabetes from 2015 to 2021
The majority of participants were female (62.85%)
Should plans continue covering them now that commercial options are available
These findings provide pertinent information for both healthcare payers (such as the National Health Service [NHS]) and prescribing physicians when considering GLP-1 receptor agonists for the treatment of type 2 diabetes in the UK
Works Best as a Complete System
